Cargando…

Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis

INTRODUCTION: The aim of this work is to perform a systematic review and meta-analysis of anti-tumor necrosis factor (anti-TNF) and anti-interleukin-17 (anti-IL-17) trials for spondyloarthritis, psoriatic arthritis, and psoriasis comparing rates of inflammatory bowel disease (IBD) events compared to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Truong, Steven L., Chin, Jasmine, Liew, David F. L., Zahir, Syeda Farah, Ryan, Elizabeth G., Rubel, Diana, Radford-Smith, Graham, Robinson, Philip C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572260/ https://www.ncbi.nlm.nih.gov/pubmed/34449067 http://dx.doi.org/10.1007/s40744-021-00360-6

Ejemplares similares

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors
por: Fieldhouse, Keira A, et al.
Publicado: (2020)

Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease
por: Krawiec, Paulina, et al.
Publicado: (2020)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Interleukin-17A and Keratinocytes in Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2020)

Interleukin-6 and rheumatic diseases
por: Lipsky, Peter E
Publicado: (2006)

Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis
por: Kaur, Rajinder, et al.
Publicado: (2018)

Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)
por: Cauli, Alberto, et al.
Publicado: (2015)

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases
por: Wasilewska, Agnieszka, et al.
Publicado: (2016)

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
por: Strand, Vibeke, et al.
Publicado: (2019)

The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
por: Schön, Michael P., et al.
Publicado: (2018)

Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
por: Pirowska, Magdalena, et al.
Publicado: (2019)

Interleukin 17 and Treg – a common pathomechanism and a new target of therapy in rheumatic diseases and depression
por: Gałecki, Piotr, et al.
Publicado: (2018)

Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2022)

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
por: Strand, Vibeke, et al.
Publicado: (2020)

Relevance of Inflammatory Cytokine mRNA Expression of Tumour Necrosis Factor- Alpha (TNF α), Interleukin 17A (IL 17A) and Interleukin 6 (IL 6) in Indian Patients with Psoriasis
por: Shah, Saiqa R., et al.
Publicado: (2022)

The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence
por: Zhang, Mengyuan, et al.
Publicado: (2021)

Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease
por: Wilke, Cailin M, et al.
Publicado: (2011)

Interleukin-17 and inflammatory bowel disease: a 2-sample Mendelian randomization study
por: Cai, Yangke, et al.
Publicado: (2023)

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
por: Menter, Alan, et al.
Publicado: (2021)

Curcumin half analog modulates interleukin-6 and tumor necrosis factor-alpha in inflammatory bowel disease
por: Kondamudi, Phani Krishna, et al.
Publicado: (2015)

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
por: Godse, Kiran
Publicado: (2017)

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
por: PHAN, Céline, et al.
Publicado: (2020)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
por: Bolt, Janne W., et al.
Publicado: (2022)

Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis
por: Jun, Yu Kyung, et al.
Publicado: (2022)

Correlations between Psoriasis and Inflammatory Bowel Diseases
por: Skroza, Nevena, et al.
Publicado: (2013)

Psoriasis and inflammatory bowel disease: links and risks
por: Vlachos, Christoforos, et al.
Publicado: (2016)

Psoriasis Features in Patients with Inflammatory Bowel Disease
por: Napolitano, Maddalena, et al.
Publicado: (2019)

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases
por: Kalden, Joachim R
Publicado: (2002)

The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis
por: Pirowska, Magdalena, et al.
Publicado: (2018)

An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients
por: Orzan, Olguța Anca, et al.
Publicado: (2023)

Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris
por: Yajima, Makiko, et al.
Publicado: (2019)

Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
por: Sánchez-Dueñas, Luis E., et al.
Publicado: (2020)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment
por: Prinz, Immo, et al.
Publicado: (2019)

Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis
por: Wang, Yan, et al.
Publicado: (2022)

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
por: Avallone, Gianluca, et al.
Publicado: (2023)

Interleukin-17 in human inflammatory diseases
por: Shabgah, Arezoo Gowhari, et al.
Publicado: (2014)

Leishmaniasis, Autoimmune Rheumatic Disease, and Anti–Tumor Necrosis Factor Therapy, Europe
por: Xynos, Ioannis D., et al.
Publicado: (2009)

Interleukin-32 as a biomarker in rheumatic diseases: A narrative review
por: Kwon, Oh Chan, et al.
Publicado: (2023)

Interleukin-17 and Interleukin-10 Association with Disease Progression in Schizophrenia
por: Chenniappan, Raghavi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3njhoku85prplfvuct0gmmaeil